4-chloro-5-sulfamoylanthranilic acid,
3086-91-7,
4-Chloro-5-sulfamoylanthranilic acid,
2-amino-4-chloro-5-sulfamoylbenzoic acid,
Saluamine,
UNII-CQE8131SF0,
2-AMINO-5-AMINOSULFONYL-4-CHLOROBENZOIC ACID,
EINECS 221-408-7,
CQE8131SF0,
2-Amino-5-(aminosulphonyl)-4-chlorobenzoic acid,
Benzoic acid, 2-amino-5-(aminosulfonyl)-4-chloro-,
2-amino-5-(aminosulfonyl)-4-chlorobenzoic acid,
Benzoic acid,2-amino-5-(aminosulfonyl)-4-chloro-,
2-amino-4-chloro-5-(aminosulfonyl)benzoic acid,
4-Chloro-5-sulfamoyl-anthranilic Acid,
Furosemide Impurity C,
Desfurylmethylfurosemide,
AC1L2R3K,
AC1Q6TR7,
ARONIS27010,
SCHEMBL3040620,
CTK4G6063,
DTXSID60184875,
CHEBI:143338,
KS-000048IE,
ZINC5783849,
STL481759,
AKOS015995696,
ACM3086917,
API0000822,
MCULE-7494137959,
LS-35612,
2-Amino-4-chloro-5-sulphamoylbenzoic Acid,
FT-0650659,
J-018174,
Furosemide Related Compound B, United States Pharmacopeia (USP) Reference Standard,
4-CHLORO-5- SULFAMOYLANTHRANILIC ACID (Furosemide Related Compound B), Pharmaceutical Secondary Standard; Certified Reference Material,
Not Available,
C7H7ClN2O4S,
FUROSEMIDERELATEDCOMPOUNDB,
C7-H7-Cl-N2-O4-S,
CID76523,
AR-1G1711,
CS-T-42092,
32251-76-6,